Pathologists at the Stanford University School of Medicine are trying out a new test from a Sunnyvale company that could give cancer patients a better chance of getting the most effective treatment.

Life Technologies acquired Pinpoint Genomics and its early-stage non-small-cell lung cancer test. The test is designed to identify early-stage patients at high risk for progression to late-stage ...